Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into australia's national childhood vaccine schedule

Jim P. Buttery, Stephen B. Lambert, Keith Grimwood, Michael D. Nissen, Emma J. Field, Kristine K. MacArtney, Jonathan D. Akikusa, Julian J. Kelly, Carl D. Kirkwood

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Introduction: Rotavirus vaccines were introduced into the funded Australian National Immunization Program (NIP) in July 2007. Due to purchasing arrangements, individual states and territories chose either a 2-dose RV1 (Rotarix, GSK) regimen or 3-dose RV5 (Rotateq, Merck/CSL) regimen. This allowed comparison of both vaccines in similar populations with high infant vaccination coverage. 

    Methods: Admission and rotavirus identification data from the major pediatric hospitals in 3 states (2 using RV5, 1 RV1), together with state-based hospitalization and vaccination data from Queensland (RV5) were analyzed for the years before, and up to 30 months following rotavirus vaccine introduction. Emergency encounters and short-stay unit admissions for gastroenteritis are also described. 

    Results: Rotavirus vaccine coverage in Australia is high, with 87% of infants receiving at least 1 dose. Hospital admissions for both rotavirus gastroenteritis and nonrotavirus-coded gastroenteritis were reduced following vaccine introduction in all states, not only for the age group eligible for NIP rotavirus vaccination, but also for children born prior. RV5 vaccine efficacy in Queensland has been estimated at 89.3%. Marked reductions in acute gastroenteritis emergency presentations and short-stay unit admissions have also been observed. 

    Conclusions: Early evidence from the NIP in Australia has demonstrated high rotavirus coverage with both RV1 and RV5. The introduction of both vaccines has been associated with a marked reduction in gastroenteritis admissions, supportive of both direct vaccine protection, as well as with indirect herd protection.

    Original languageEnglish
    Pages (from-to)S25-S29
    Number of pages5
    JournalPediatric Infectious Disease Journal
    Volume30
    Issue number1
    DOIs
    Publication statusPublished - Jan 2011

    Fingerprint

    Rotavirus Vaccines
    Rotavirus
    Gastroenteritis
    Appointments and Schedules
    Vaccines
    Immunization Programs
    Vaccination
    Queensland
    Emergencies
    Pediatric Hospitals
    Hospitalization
    Age Groups
    Population

    Cite this

    Buttery, Jim P. ; Lambert, Stephen B. ; Grimwood, Keith ; Nissen, Michael D. ; Field, Emma J. ; MacArtney, Kristine K. ; Akikusa, Jonathan D. ; Kelly, Julian J. ; Kirkwood, Carl D. / Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into australia's national childhood vaccine schedule. In: Pediatric Infectious Disease Journal. 2011 ; Vol. 30, No. 1. pp. S25-S29.
    @article{98e8145ba50c4748be06b8c96a04d0fb,
    title = "Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into australia's national childhood vaccine schedule",
    abstract = "Introduction: Rotavirus vaccines were introduced into the funded Australian National Immunization Program (NIP) in July 2007. Due to purchasing arrangements, individual states and territories chose either a 2-dose RV1 (Rotarix, GSK) regimen or 3-dose RV5 (Rotateq, Merck/CSL) regimen. This allowed comparison of both vaccines in similar populations with high infant vaccination coverage. Methods: Admission and rotavirus identification data from the major pediatric hospitals in 3 states (2 using RV5, 1 RV1), together with state-based hospitalization and vaccination data from Queensland (RV5) were analyzed for the years before, and up to 30 months following rotavirus vaccine introduction. Emergency encounters and short-stay unit admissions for gastroenteritis are also described. Results: Rotavirus vaccine coverage in Australia is high, with 87{\%} of infants receiving at least 1 dose. Hospital admissions for both rotavirus gastroenteritis and nonrotavirus-coded gastroenteritis were reduced following vaccine introduction in all states, not only for the age group eligible for NIP rotavirus vaccination, but also for children born prior. RV5 vaccine efficacy in Queensland has been estimated at 89.3{\%}. Marked reductions in acute gastroenteritis emergency presentations and short-stay unit admissions have also been observed. Conclusions: Early evidence from the NIP in Australia has demonstrated high rotavirus coverage with both RV1 and RV5. The introduction of both vaccines has been associated with a marked reduction in gastroenteritis admissions, supportive of both direct vaccine protection, as well as with indirect herd protection.",
    author = "Buttery, {Jim P.} and Lambert, {Stephen B.} and Keith Grimwood and Nissen, {Michael D.} and Field, {Emma J.} and MacArtney, {Kristine K.} and Akikusa, {Jonathan D.} and Kelly, {Julian J.} and Kirkwood, {Carl D.}",
    year = "2011",
    month = "1",
    doi = "10.1097/INF.0b013e3181fefdee",
    language = "English",
    volume = "30",
    pages = "S25--S29",
    journal = "Pediatric Infectious Disease Journal",
    issn = "0891-3668",
    publisher = "Lippincott Williams & Wilkins",
    number = "1",

    }

    Buttery, JP, Lambert, SB, Grimwood, K, Nissen, MD, Field, EJ, MacArtney, KK, Akikusa, JD, Kelly, JJ & Kirkwood, CD 2011, 'Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into australia's national childhood vaccine schedule', Pediatric Infectious Disease Journal, vol. 30, no. 1, pp. S25-S29. https://doi.org/10.1097/INF.0b013e3181fefdee

    Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into australia's national childhood vaccine schedule. / Buttery, Jim P.; Lambert, Stephen B.; Grimwood, Keith; Nissen, Michael D.; Field, Emma J.; MacArtney, Kristine K.; Akikusa, Jonathan D.; Kelly, Julian J.; Kirkwood, Carl D.

    In: Pediatric Infectious Disease Journal, Vol. 30, No. 1, 01.2011, p. S25-S29.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into australia's national childhood vaccine schedule

    AU - Buttery, Jim P.

    AU - Lambert, Stephen B.

    AU - Grimwood, Keith

    AU - Nissen, Michael D.

    AU - Field, Emma J.

    AU - MacArtney, Kristine K.

    AU - Akikusa, Jonathan D.

    AU - Kelly, Julian J.

    AU - Kirkwood, Carl D.

    PY - 2011/1

    Y1 - 2011/1

    N2 - Introduction: Rotavirus vaccines were introduced into the funded Australian National Immunization Program (NIP) in July 2007. Due to purchasing arrangements, individual states and territories chose either a 2-dose RV1 (Rotarix, GSK) regimen or 3-dose RV5 (Rotateq, Merck/CSL) regimen. This allowed comparison of both vaccines in similar populations with high infant vaccination coverage. Methods: Admission and rotavirus identification data from the major pediatric hospitals in 3 states (2 using RV5, 1 RV1), together with state-based hospitalization and vaccination data from Queensland (RV5) were analyzed for the years before, and up to 30 months following rotavirus vaccine introduction. Emergency encounters and short-stay unit admissions for gastroenteritis are also described. Results: Rotavirus vaccine coverage in Australia is high, with 87% of infants receiving at least 1 dose. Hospital admissions for both rotavirus gastroenteritis and nonrotavirus-coded gastroenteritis were reduced following vaccine introduction in all states, not only for the age group eligible for NIP rotavirus vaccination, but also for children born prior. RV5 vaccine efficacy in Queensland has been estimated at 89.3%. Marked reductions in acute gastroenteritis emergency presentations and short-stay unit admissions have also been observed. Conclusions: Early evidence from the NIP in Australia has demonstrated high rotavirus coverage with both RV1 and RV5. The introduction of both vaccines has been associated with a marked reduction in gastroenteritis admissions, supportive of both direct vaccine protection, as well as with indirect herd protection.

    AB - Introduction: Rotavirus vaccines were introduced into the funded Australian National Immunization Program (NIP) in July 2007. Due to purchasing arrangements, individual states and territories chose either a 2-dose RV1 (Rotarix, GSK) regimen or 3-dose RV5 (Rotateq, Merck/CSL) regimen. This allowed comparison of both vaccines in similar populations with high infant vaccination coverage. Methods: Admission and rotavirus identification data from the major pediatric hospitals in 3 states (2 using RV5, 1 RV1), together with state-based hospitalization and vaccination data from Queensland (RV5) were analyzed for the years before, and up to 30 months following rotavirus vaccine introduction. Emergency encounters and short-stay unit admissions for gastroenteritis are also described. Results: Rotavirus vaccine coverage in Australia is high, with 87% of infants receiving at least 1 dose. Hospital admissions for both rotavirus gastroenteritis and nonrotavirus-coded gastroenteritis were reduced following vaccine introduction in all states, not only for the age group eligible for NIP rotavirus vaccination, but also for children born prior. RV5 vaccine efficacy in Queensland has been estimated at 89.3%. Marked reductions in acute gastroenteritis emergency presentations and short-stay unit admissions have also been observed. Conclusions: Early evidence from the NIP in Australia has demonstrated high rotavirus coverage with both RV1 and RV5. The introduction of both vaccines has been associated with a marked reduction in gastroenteritis admissions, supportive of both direct vaccine protection, as well as with indirect herd protection.

    UR - http://www.scopus.com/inward/record.url?scp=78751549733&partnerID=8YFLogxK

    U2 - 10.1097/INF.0b013e3181fefdee

    DO - 10.1097/INF.0b013e3181fefdee

    M3 - Article

    VL - 30

    SP - S25-S29

    JO - Pediatric Infectious Disease Journal

    JF - Pediatric Infectious Disease Journal

    SN - 0891-3668

    IS - 1

    ER -